RMD logo

ResMed Inc. (RMD)

$242.61

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on RMD

Market cap

$34.12B

EPS

10.98

P/E ratio

22

Price to sales

5.72

Dividend yield

1.088%

Beta

0.770447

Price on RMD

Previous close

$237.85

Today's open

$236.38

Day's range

$236.14 - $246.14

52 week range

$180.27 - $277.67

Profile about RMD

CEO

Michael J. Farrell

Employees

11370

Headquarters

San Diego, CA

Exchange

New York Stock Exchange

Shares outstanding

140657071

Issue type

Common Stock

RMD industries and sectors

Healthcare

Medical Equipment & Supplies

News on RMD

Top 50 High-Quality Dividend Growth Stocks For November 2026

I track 50 high-quality dividend growth stocks to identify favorable entry points, prioritizing long-term total return alongside a growing dividend stream. Forty stocks offer estimated future returns of at least 10%; 27 appear undervalued relative to historical free cash flow. ResMed leads with 41.60% estimated return potential; MarketAxess rose to fifth at 28.50% after a valuation upgrade and higher fair value estimate.

news source

Seeking Alpha • Nov 14, 2026

news preview

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of ResMed Inc. (NYSE: RMD).

NEW YORK, Nov. 9, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of ResMed Inc. (NYSE: RMD) concerning possible breaches of fiduciary duties. If you are a current shareholder of RMD, you can request additional information here: https://zlk.com/cases/resmed-inc-investigation-rmd or contact Joseph E.

news source

PRNewsWire • Nov 10, 2026

news preview

Don't Lose Sleep Over GLP-1s: Why ResMed Is a Bargain

ResMed, whose devices treat sleep apnea, has dropped on unfounded concerns that weight-loss drugs will replace its treatment. The stock is cheap and worth buying at current prices.

news source

Barrons • Nov 5, 2026

news preview

Top 10 High Growth Dividend Stocks For November 2026

I present 10 high-quality dividend growth stocks with strong total return potential, screened for robust fundamentals and attractive valuations as of November 2026. Key criteria include Investment Score ≥70, future return potential ≥12%, consistent 7%+ dividend growth, and payout ratios below 100%. Top picks such as RMD, NTES, and NVDA offer compelling upside, with future return estimates driven by EPS growth, yield, and potential valuation mean reversion.

news source

Seeking Alpha • Nov 5, 2026

news preview

ResMed: 3 Key Takeaways for Long-Term Investors

ResMed reported that core constant currency revenue grew 7% in the first quarter. Patients on GLP-1 drugs are 11% more likely to start CPAP therapy.

news source

The Motley Fool • Nov 2, 2026

news preview

What ResMed (RMD) Said on Its Q1 Earnings Call

ResMed NYSE: RMD reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% from a year earlier on a reported basis and 7% on a core constant-currency basis, as growth in sleep devices, masks and residential care software offset declines in life-support device sales. Non-GAAP diluted earnings per share rose 14% to $2.91.

news source

MarketBeat • Oct 30, 2026

news preview

RMD Stock Up on Q1 Earnings and Revenue Beat, Gross Margin Climbs

ResMed's first-quarter fiscal 2027 earnings and revenues top estimates as sustained sleep device demand, productivity gains and gross margin expansion drive growth.

news source

Zacks Investment Research • Oct 30, 2026

news preview

ResMed (RMD) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

news source

Zacks Investment Research • Oct 30, 2026

news preview

ResMed Inc. (RMD) Q1 2027 Earnings Call Transcript

ResMed Inc. (RMD) Q1 2027 Earnings Call Transcript

news source

Seeking Alpha • Oct 30, 2026

news preview

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027

Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at  http://investor.resmed.com

news source

GlobeNewsWire • Oct 29, 2026

news preview

¹ Disclosures

Get started with M1

Invest in ResMed Inc.

Open an M1 investment account to buy and sell ResMed Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in RMD on M1